Literature DB >> 17522851

Specific features of sensorimotor cerebral cortex activity modulation by dopamine releaser amantadine.

Viktor M Storozhuk1, Larissa E Zinyuk.   

Abstract

The modulatory effects of amantadine (1-adamantanamine) on the activity of sensorimotor cerebral cortex neurones during microiontophoretic application of agonists of glutamatergic and GABA-ergic (gamma-aminobutyric acid) transmission were studied. In non-anaesthetised cats, dopamine (DA) released by amantadine application in a small area of the neocortex increased baseline and evoked neuronal activity, providing stabilization and optimum course of both the neuronal and the conditioned responses of the animal. Amantadine eliminates a decrease in the level of neuronal baseline and evoked activity and marked increase in the latency of neuronal activation and conditioned movement mediated by D2 receptor antagonist sulpiride ((S)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl) methyl]-2-methoamantadineybenzamide) or GABA. This is reflected by a proportionate decrease in the onset of neuronal impulse reaction and latency of conditioned movement. Combined NMDA (N-methyl-D: -aspartate) and amantadine application also caused a considerable increase in baseline and evoked activity, but produced a slightly weaker effect than that evoked by NMDA application alone. A decrease in the baseline and evoked neuronal activity after NMDA withdrawn lasted during next control session (up to 40 min). The ability of DA releaser amantadine to alleviate significant increase in the latency of neuronal responses and conditioned movement induced by sulpiride or GABA suggests that dopamine modulates the activity of GABA-ergic inhibitory fast spike interneurons in the cat sensorimotor cortex during conditioning.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522851     DOI: 10.1007/s00221-007-0976-2

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  36 in total

1.  Scheduling of monoaminergic neurotransmitter receptor expression in the primate neocortex during postnatal development.

Authors:  M S Lidow; P Rakic
Journal:  Cereb Cortex       Date:  1992 Sep-Oct       Impact factor: 5.357

2.  D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization.

Authors:  E C Muly; K Szigeti; P S Goldman-Rakic
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

3.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

4.  Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET).

Authors:  M F Kraus; G S Smith; M Butters; A J Donnell; E Dixon; C Yilong; D Marion
Journal:  Brain Inj       Date:  2005-07       Impact factor: 2.311

5.  Functional development of the prefrontal cortex in early life and the problem of neuronal plasticity.

Authors:  P S Goldman
Journal:  Exp Neurol       Date:  1971-09       Impact factor: 5.330

6.  Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons.

Authors:  J K Seamans; N Gorelova; D Durstewitz; C R Yang
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

7.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

Review 8.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

9.  Basal ganglia and cerebral cortical distribution of dopamine D1- and D2-receptors in neonatal and adult cat brain.

Authors:  E K Richfield; D L Debowey; J B Penney; A B Young
Journal:  Neurosci Lett       Date:  1987-01-27       Impact factor: 3.046

10.  Dopamine: release from the brain in vivo by amantadine.

Authors:  P F Von Voigtlander; K E Moore
Journal:  Science       Date:  1971-10-22       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.